關於我們About Us

致力於核酸新藥開發，鎖定肝臟疾病治療 Developing Nucleic Acid Therapeutics for Liver Disease

台灣基因核酸新藥股份有限公司（台基核, COGENTIDE）專注於 ASO 核酸新藥之序列設計與篩選，並具備新劑型藥物之共同開發與執行能力。我們建立自有之序列演算法與動物模式篩選平台，並與學研機構合作驗證候選新藥效力，逐步建構從序列設計到候選新藥的完整開發鏈。 Taiwan CoGentide Novel Drug Corp. (CoGentide) focuses on the design and screening of ASO nucleic acid drugs, alongside co-development and execution capabilities for new drug formulations. We've built our own sequence algorithm and animal model screening platforms, and work with academic partners to validate candidate efficacy — building a complete development chain from sequence design to drug candidate.

台基核團隊會議協作情境

使命 MissionMission

以自建序列演算法平台為核心，系統化篩選並驗證核酸候選新藥，加速肝臟疾病等重大未滿足醫療需求的治療選項落地。 Using our proprietary sequence algorithm platform, we systematically screen and validate candidate nucleic acid drugs to accelerate treatment options for liver disease and other areas of significant unmet medical need.

願景 VisionVision

以自主研發的核酸新藥為根基，逐步建立從實驗室到臨床申請的完整轉譯能力，讓核酸新藥真正走進病人的治療選擇。 Built on our own nucleic acid drug pipeline, we're steadily establishing a complete translational path from lab to clinical submission — bringing nucleic acid therapeutics into real treatment choices for patients.

核心能力Core Capabilities

ASO 核酸新藥設計與篩選平台 ASO Novel Drug Design and Screening Platform

自主設計 ASO 篩選邏輯與評估標準，建立自動化篩選流程，並建構候選序列細胞驗證平台，所有分析標準與數據，智財皆歸台基核。 We independently design ASO screening logic and evaluation criteria, have built an automated screening workflow, and maintain a candidate sequence validation platform, with all analytical standards and data owned by CoGentide.

免疫健全肝癌動物模式 Immunocompetent Liver Tumor Animal Model

建立免疫健全 HBV 相關肝腫瘤動物模式，具高成瘤重現性與完整免疫微環境，作為候選新藥藥效驗證平台，亦可延伸應用於其他肝臟腫瘤篩選。 We've developed an immunocompetent HBV-related liver tumor model with high tumor reproducibility and an intact immune microenvironment, serving as our core platform for candidate efficacy validation — with potential to extend to screening for other liver tumors.

藥品開發執行與轉譯能力 Drug Development Execution and Translational Capability

與同業合作開發新劑型藥物，採 505(b)(2) 路徑，由台基核主導配方測試、臨床前開發與法規申請，為獨立於核酸新藥開發之產品線，展現團隊執行力並貢獻營收基礎。 Through industry partnerships, we develop new drug formulations via the 505(b)(2) pathway, with CoGentide leading formulation testing, preclinical development, and regulatory filing. This is an independent product line from our nucleic acid drug development, demonstrating our execution capability and contributing to our revenue base.

與學研機構協力，強化平台執行深度 Working with Academic Partners to Strengthen Execution

台大生命科學院 台大醫學院 長庚大學

我們與台大生命科學院合作，協助序列演算法之程式化與自動流程建置；與台大醫學院合作建立疾病動物模式；並與長庚大學合作執行候選序列之細胞功效驗證。核心設計邏輯與決策皆由台基核主導，學研合作聚焦於專業執行與經驗支援。 We collaborate with NTU's College of Life Science on algorithm coding and automation infrastructure; with NTU's College of Medicine on our disease animal models; and with Chang Gung University on cell-based efficacy validation of candidate sequences. Core design logic and decision-making remain led by CoGentide, with academic partners contributing specialized execution and experience.

近期成果Recent Milestones

  • 1

    完成 ASO 設計演算法開發，並以 3 款上市藥物標靶序列驗證篩選能力 Completed development of the ASO design algorithm, validated against target sequences of 3 marketed drugs

  • 2

    已於多個肝癌細胞株中篩選出具潛力之 TERT ASO 候選序列，相關驗證仍在進行中 Identified promising TERT ASO candidate sequences across multiple liver cancer cell lines; validation is ongoing

  • 3

    免疫健全 HBV 相關肝腫瘤動物模式建立完成，提出 PCT 及台灣發明專利申請 Completed development of the immunocompetent HBV-related liver tumor model; filed PCT and Taiwan patent applications

  • 4

    與同業合作推進新劑型開發案，完成成分與功效分析方法建立 Advanced a new formulation development program with an industry partner; established methods for composition and efficacy analysis

與我們展開合作對話Let's Start a Conversation

無論是授權合作、共同開發，或學研合作，歡迎與我們的團隊聯繫，進一步了解台基核的核酸新藥開發進程。 Whether you're exploring licensing, co-development, or academic collaboration, we'd love to hear from you.

聯絡我們Contact Us